|Nombre||Título||Pagar||Ejecutado||Año de nacimiento|
|Mr. Mark T. Iwicki||Chairman, Pres & CEO||889.9k||N/D||1966|
|Mr. Todd Bazemore||Chief Operating Officer||237.7k||N/D||1970|
|Dr. Kim Brazzell||Chief Medical Officer||591.83k||N/D||1953|
|Dr. Justin Hanes Ph.D.||Founder & Chair of the Scientific Advisory Board||N/D||N/D||N/D|
|Ms. Mary Reumuth CPA||CFO & Treasurer||N/D||N/D||1975|
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. Its product candidates include KPI-121 1.0%, which has completed Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; INVELTYS that has completed Phase III clinical trials for the temporary relief of the signs and symptoms of dry eye disease; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.
La calificación ISS Governance QuickScore de Kala Pharmaceuticals, Inc. a partir del 1 de febrero de 2019 es 9. Las puntuaciones principales son Auditoría: 2; Junta: 9; Derechos del accionista: 8; Compensación: 8.